Cyr61/CCN1 displays high-affinity binding to the somatomedin B 1-44 domain of vitronectin

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Francischetti, Ivo M B ^a   Kotsyfakis, Michalis ^b   Andersen, John F ^a   Lukszo, Jan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b INSTITUTE OF PARASITOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CYSTEINE RICH PROTEIN 61; EPITOPE; SOMATOMEDIN B; VITRONECTIN; VITRONECTIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN;

ANGIOGENESIS; ARTICLE; BINDING ASSAY; BINDING SITE; CELL ADHESION; CELL STRAIN U937; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMOBILIZATION; ISOTHERMAL TITRATION CALORIMETRY; PROTEIN ANALYSIS; PROTEIN INTERACTION; SOLID; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; BINDING COMPETITION; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BINDING SITES; BINDING, COMPETITIVE; CYSTEINE-RICH PROTEIN 61; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTEGRIN ALPHAVBETA3; MOLECULAR SEQUENCE DATA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SEQUENCE HOMOLOGY, AMINO ACID; SOMATOMEDINS; SURFACE PLASMON RESONANCE; U937 CELLS; VITRONECTIN;

EID: 77949674681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009356     Document Type: Article

References (55)

1. Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family. Endocr Rev 20: 189-206.
2. Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803-4810.
3. Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33: 461-473.
4. Bach LA, Headey SJ, Norton RS (2005) IGF-binding proteins - the pieces are falling into place. Trends Endocrinol Metab 16: 228-234.
5. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854.
6. Mohan S, Baylink DJ (2002) IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175: 19-31.
7. Nam T, Moralez A, Clemmons D (2002) Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 143: 30-36.
8. Preissner KT (1991) Structure and biological role of vitronectin. Annu Rev Cell Biol 7: 275-310.
9. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264: 569-571.
10. Kleinman HK, Philp D, Hoffman MP (2003) Role of the extracellular matrix in morphogenesis. Curr Opin Biotechnol 14: 526-532.
11. Hynes RO (2007) Cell-matrix adhesion in vascular development. J Thromb Haemost 5 Suppl 1: 32-40.
12. Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631-640.
13. Cale JM, Lawrence DA (2007) Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent. Curr Drug Targets 8: 971-981.
14. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT (1993) Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 268: 22874-22882.
15. Okumura Y, Kamikubo Y, Curriden SA, Wang J, Kiwada T, et al. (2002) Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 277: 9395-9404.
16. Kamikubo Y, Kroon G, Curriden SA, Dyson HJ, Loskutoff DJ (2006) The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule. Biochemistry 45: 3297-3306.
17. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544.
18. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571.
19. Kjaergaard M, Gardsvoll H, Hirschberg D, Nielbo S, Mayasundari A, et al. (2007) Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci 16: 1934-1945.
20. Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB (2004) The solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migration. J Biol Chem 279: 29359-29366.
21. Schar CR, Blouse GE, Minor KH, Peterson CB (2008) A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J Biol Chem 283: 10297-10309.
22. Schar CR, Jensen JK, Christensen A, Blouse GE, Andreasen PA, et al. (2008) Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 283: 28487-28496.
23. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, et al. (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388.
24. Kjaergaard M, Hansen LV, Jacobsen B, Gardsvoll H, Ploug M (2008) Structure and ligand interactions of the urokinase receptor (uPAR). Front Biosci 13: 5441-5461.
25. Francischetti IM, Valenzuela JG, Andersen JF, Mather TN, Ribeiro JM (2002) Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 99: 3602-3612.
26. Francischetti IM, Seydel KB, Monteiro RQ (2008) Blood coagulation, inflammation, and malaria. Microcirculation 15: 81-107.
27. Morton TA, Myszka DG, Chaiken IM (1995) Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. Anal Biochem 227: 176-185.
28. Leavitt S, Freire E (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr Opin Struct Biol 11: 560-566.
29. Seiffert D (1995) Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. FEBS Lett 368: 155-159.
30. Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ (1994) The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269: 2659-2666.
31. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, et al. (2008) Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 15: 422-423.
32. Nusrat AR, Chapman HA, Jr. (1991) An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 87: 1091-1097.
33. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189: 23-33.
34. Rovera G, Santoli D, Damsky C (1979) Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci U S A 76: 2779-2783.
35. Yang GP, Lau LF (1991) Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 2: 351-357.
36. Nishida T, Kubota S, Fukunaga T, Kondo S, Yosimichi G, et al. (2003) CTGF/ Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes. J Cell Physiol 196: 265-275.
37. Desnoyers L, Arnott D, Pennica D (2001)WISP-1 binds to decorin and biglycan. J Biol Chem 276: 47599-47607.
38. Seiffert D (1997) Constitutive and regulated expression of vitronectin. Histol Histopathol 12: 787-797.
39. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, et al. (2002) Cyr61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 22: 8709-8720.
40. Aaboe M, Offersen BV, Christensen A, Andreasen PA (2003) Vitronectin in human breast carcinomas. Biochim Biophys Acta 1638: 72-82.
41. Kenny HA, Kaur S, Coussens LM, Lengyel E (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118: 1367-1379.
42. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, et al. (1996) Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 62: 260-267.
43. Jaskiewicz K, Chasen MR, Robson SC (1993) Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res 13: 2229-2237.
44. Bafetti LM, Young TN, Itoh Y, Stack MS (1998) Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 273: 143-149.
45. Nip J, Shibata H, Loskutoff DJ, Cheresh DA, Brodt P (1992) Human melanoma cells derived from lymphatic metastases use integrin αvβ3 to adhere to lymph node vitronectin. J Clin Invest 90: 1406-1413.
46. O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, et al. (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33: 59-67.
47. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N (2007) uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 177: 927-939.
48. Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, et al. (2005) Regulation of a5b1 integrin conformation and function by urokinase receptor binding. J Cell Biol 168: 501-511.
49. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT (1998) Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91: 2305-2312.
50. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968.
51. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, et al. (2002) Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296: 151-155.
52. Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT (1992) Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267: 12098-12105.
53. Hildebrand A, Preissner KT, Muller-Berghaus G, Teschemacher H (1989) A novel β-endorphin binding protein. Complement S protein ( = vitronectin) exhibits specific non-opioid binding sites for β-endorphin upon interaction with heparin or surfaces. J Biol Chem 264: 15429-15434.
54. Calvo E, Tokumasu F, Marinotti O, Villeval JL, Ribeiro JM, et al. (2007) Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin α2β1, and von Willebrand factor. J Biol Chem 282: 26928-26938.
55. Kotsyfakis M, Sa-Nunes A, Francischetti IM, Mather TN, Andersen JF, et al. (2006) Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem 281: 26298-26307.